Bavarian Nordic A/S
OTC: BVNKF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Paul Chaplin
- Employees
- 1,744
- Headquarters
- Hellerup, Denmark
- IPO year
- 2010
- Market cap
- $2.1B
- Website
- https://www.bavarian-nordic.com
Loading BVNKF…
Loading profile data…Frequently asked questions about BVNKF
What does Bavarian Nordic A/S (BVNKF) do?
Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1,...
Where does BVNKF trade?
Bavarian Nordic A/S (BVNKF) trades on the Other OTC.
What sector is BVNKF in?
Bavarian Nordic A/S (BVNKF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Bavarian Nordic A/S?
Paul Chaplin is the chief executive officer of Bavarian Nordic A/S (BVNKF).
Where is Bavarian Nordic A/S headquartered?
Bavarian Nordic A/S is headquartered in Denmark.
Does BVNKF pay a dividend?
Bavarian Nordic A/S (BVNKF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BVNKF go public?
Bavarian Nordic A/S (BVNKF) completed its initial public offering in 2010.